We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 110.00 | 105.00 | 115.00 | 110.00 | 110.00 | 110.00 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -5.03 | 14.67M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/10/2016 11:01 | Good results from 2 days ago. Bit of chat on Vox Markets - starts 42:20. And more buying than selling. | lr2 | |
21/10/2016 10:47 | Low cash but they are dealing with £2k monthly cash burn from may to October how long will that take to cover? | felix60 | |
21/10/2016 10:33 | any clues as to why the spike? | qs99 | |
19/10/2016 07:27 | Nice rns.. Future looking good although cash levels low | letmepass | |
12/10/2016 15:56 | A little top up on today's pull back. Low risk I think. Finals last year 6th Nov. | martinthebrave | |
05/10/2016 11:26 | Slowly moving up, low number of shares and news this month | letmepass | |
05/10/2016 08:36 | FEEDBARK on the move | risk1 | |
04/10/2016 08:35 | Volume picking up..should be over 2 today awaiting news | letmepass | |
28/9/2016 09:02 | During the year, TexRAD has been purchased by institutions including ELK in Berlin, Velindre Cancer Centre in Cardiff, University of Tokyo Department of Radiology at the Institute of Medical Science in Japan, CHU de Reims in France and Seoul National University Bundang Hospital in South Korea, among others. | letmepass | |
27/9/2016 08:58 | Might try a small top up before Oct.. | letmepass | |
23/9/2016 08:34 | Next news October which could be very interesting | letmepass | |
22/9/2016 09:37 | Nothing goes up in straight lines this has massive potential should find its way to several pence short term | mally6 | |
22/9/2016 08:43 | Yesterday biggest riser, today biggest loser | letmepass | |
22/9/2016 08:11 | Some are sells... | letmepass | |
22/9/2016 08:09 | craft mm tricks....the buys are looking like sells. Done a dummy trade online and you can buy well under 2.5 | king kong dong | |
21/9/2016 23:38 | Nice article in Daily Mail with chart | zico01 | |
21/9/2016 23:36 | STOCK WATCH - FEEDBACK Shares in medical imaging tool company Feedback more than doubled yesterday on a confident trading update. One of its products is TexRAD, which allows users to look at textures in medical images. Feedback is making progress on a way to integrate the device with scanners in UK hospitals. It has been demonstrating a prototype to potential users and said orders had increased significantly. Feedback said full-year results in October should show turnover significantly up on last year. Shares rose 156 per cent, or 1.3p, to 2.18p. | zico01 | |
21/9/2016 22:34 | There has been a focus on developing strategic collaborations for TexRAD while continuing the sales of research versions to world-leading research institutions. During the year, TexRAD has been purchased by institutions including ELK in Berlin, Velindre Cancer Centre in Cardiff, University of Tokyo Department of Radiology at the Institute of Medical Science in Japan, CHU de Reims in France and Seoul National University Bundang Hospital in South Korea, among others. The company was also delighted to announce on 9 September 2015 that TexRAD had completed its first sale to China with an installation at Peking University Medical College Hospital, Beijing. We have also worked closely with leading research groups with a view to commercialising TexRAD for specific applications. Since the year end and following the highly encouraging early results from a retrospective study into TexRAD's potential use in the treatment of urolithiasis (formation of kidney stones), the Company formed a joint venture company, Stone Checker Software Ltd ('Stone Checker'). Stone Checker will use our intellectual property in conjunction with other biomarkers to develop an integrated product to assist clinicians to determine which stones are most likely to respond to shock wave lithotripsy. We have, in the new financial year, formed another joint venture company, Prostate Checker Ltd to target a more effective method of diagnosing and assessing treatment options for prostate cancer. | letmepass | |
21/9/2016 22:32 | More news October.. Very interesting.. Market cap 3m..possibly 100m in a year | letmepass | |
21/9/2016 22:29 | Elucid recent not an old copy... The number of new purchase orders received for TexRAD research versions has increased significantly in recent months leading to expectations of a much improved cash inflow over the next few months. | letmepass | |
21/9/2016 22:28 | I like this The Board believes the future for Feedback is hugely promising and we look forward to working closely with Alliance and developing our other collaborative ventures. | letmepass | |
21/9/2016 22:08 | low on cash balance! Interim Results for the six months ended 30 November 2015 The cash balance as at 30 November 2015 was £164,000 | euclid5 | |
21/9/2016 16:38 | My take: Collectoral cancer screening programmes are being taken nationwide, Luxembourg the latest to give it to 55-plussers. So a new, more efficient scan technique in that field should be well received. | andrbea |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions